In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nomos takes ultrasound-guided radiation therapy to China

This article was originally published in Clinica

Executive Summary

North American Scientific's radiation oncology division, Nomos, has received approval in China to market its ultrasound system for viewing cancerous tumors prior to the delivery of radiation therapy. The image-guided radiation therapy (IGRT) system, called BAT Sxi, is designed to be compatible with all linear accelerators and most treatment planning products, said the Chatsworth, California firm. Noting that it had gained Chinese market go-ahead for its Peacock intensity-modulated radiation therapy (IMRT) product in September 2005, the company said it remained hopeful that it would have its full range of products available in China during fiscal 2006. The firm is also in the process of registering in China its Prospera I-125 brachytherapy seeds for treating prostate cancer.

You may also be interested in...



FDA Re-Evaluates Orange Book Patents

With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.

Mylan And Lupin Prepare To Launch EU Etanercept

Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.

FTC Notifies ReJuvenation ‘Anti-Aging’ Pill Purchasers To Expect (Or Request) Mailed Refunds

The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.

Topics

UsernamePublicRestriction

Register

MT142249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel